#USA #New York #Healthcare Conference #Trevi Therapeutics #Haduvio

Trevi Therapeutics to Make an Impact at Stifel 2025 Healthcare Conference

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a promising clinical-stage biopharmaceutical firm, is set to highlight its innovative investigational therapy, Haduvio™ (oral nalbuphine ER), at the upcoming Stifel 2025 Healthcare Conference. This event, scheduled for November 11-12 in New York, offers a unique opportunity for the company to showcase its work in treating chronic coughs associated with idiopathic pulmonary fibrosis (IPF) and other related conditions.

Important Participation Insights

On November 11, at 3:20 p.m. ET, Jennifer Good, President and CEO of Trevi, alongside Dr. James Cassella, the Chief Development Officer, will partake in a fireside chat. This session is likely to provide insightful discussions regarding Trevi's ongoing research and the potential impact of Haduvio. Furthermore, they will engage in a series of investor meetings throughout the event, fostering connections with key stakeholders in the healthcare sector.

Understanding Haduvio™

Haduvio is a groundbreaking therapy currently under investigation for its efficacy in managing chronic cough, particularly in patients suffering from IPF and non-IPF interstitial lung disease, as well as those with refractory chronic cough (RCC). What sets Haduvio apart is its dual action as a kappa agonist and mu antagonist (KAMA), effectively targeting the cough reflex arc both centrally and peripherally.

Chronic cough is a pressing issue for many patients, especially those with IPF, where approximately two-thirds experience uncontrollable coughing episodes. The staggering data shows that around 150,000 individuals in the U.S. are diagnosed with IPF, with many suffering from challenging and disruptive chronic coughs. Similarly, non-IPF interstitial lung disease affects about 228,000 people in the U.S., with a significant portion grappling with uncontrolled cough issues. The repercussions of such a condition are severe, often leading to a decline in patients' quality of life, increased healthcare costs, and heightened risks of morbidity.

The Challenge of Refractory Chronic Cough (RCC)

RCC presents another layer of complexity in cough management. Defined as a cough that persists for over eight weeks despite treatment for underlying conditions, RCC significantly impacts the physical, psychological, and social well-being of patients. Estimates suggest that 2 to 3 million individuals in the U.S. are affected by RCC, and its management is hindered due to the absence of FDA-approved therapies. As Trevi Therapeutics aims to propose Haduvio as a trade name for oral nalbuphine ER, the anticipation for clinical trials and regulatory evaluations continues to grow.

Commitment to Innovation

Trevi Therapeutics is dedicated to advancing the understanding and treatment of chronic cough, especially in underrepresented areas with significant unmet medical needs. Haduvio's unique mechanism of action could redefine treatment paradigms and enhance the quality of life for countless patients battling chronic conditions.

For continuous updates on Trevi's progress and initiatives, interested individuals can visit Trevi Therapeutics' official website as well as follow their activities on social media platforms such as X (formerly Twitter) and LinkedIn.

This forthcoming conference serves not just as a platform for disclosure but as a significant milestone in Trevi's path toward making strides in healthcare innovation. As the healthcare landscape continually evolves, Trevi remains poised at the forefront, ready to make impactful contributions in the biopharmaceutical field.